Transfusion medicine reviews · 2013
Anti-KANNO: a novel alloantibody against a red cell antigen of high frequency.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawabata Kinuyo, Uchikawa Makoto, Ohto Hitoshi, Yasuda Hiroyasu, Tsuneyama Hatsue, Tsuchida Hideaki, Ito Shoichi
Аннотация
We encountered a broadly reactive red cell alloantibody in 1991, reacting unlike any other known antibody, and named it anti-KANNO after the first patient. A total of 28 cases of anti-KANNO in the Japanese literature were reviewed. To distinguish KANNO from other antibodies against high-frequency antigens, including anti-JMH, anti-Ch/Rg, and anti-Jr(a), we conducted serologic studies with proteolytic enzyme and chemical treatments, complement sensitization against red cells, and serum neutralization techniques. Reactivity of anti-KANNO against red cells lacking high-frequency antigens and antisera to high-frequency antigens against KANNO cells were tested. Among the 28 patients, 26 were female, of whom 25 had a history of pregnancy. Red cells from patient KANNO were reactive with antisera against antigens of high frequency. Anti-KANNO reacted weakly with all cells known to lack high-frequency antigens. It reacted with 2-aminoethylisothiouronium bromide, so it can be distinguished from anti-JMH. Differences among anti-KANNO, anti-Ch/Rg, and anti-Jr(a) emerged with enzyme-treated cells, complement-sensitized cells, and the addition of normal serum. As yet, there are no reports of hemolytic transfusion reaction or hemolytic disease of the fetus and newborn attributable to anti-KANNO. It appears that anti-KANNO is a newly characterized antibody more likely stimulated by pregnancy than by transfusion and with little or no clinical significance. Further surveillance and investigation of anti-KANNO, its antigen biochemistry, and its genetics are warranted.
Предметные рубрики MeSH
Aged, 80 and overAnemiaAntibody SpecificityAntineoplastic AgentsBlood Group AntigensBlood Group IncompatibilityBlood Grouping and CrossmatchingBlood TransfusionErythroblastosis, FetalErythrocytesFemaleGlycoproteinsHumansInfant, NewbornIsoantibodiesLeiomyomaLeukemia, Myelomonocytic, ChronicMaleMiddle AgedParityPregnancyUterine Neoplasms